Multidisciplinary management, standards of care and future perspectives.

Co-Chairs
Nicoletta Colombo, Italy
Philipp Harter, Germany
ESMO PRECEPTORSHIP PROGRAMME
OVARIAN CANCER
Multidisciplinary management, standards of care and future perspectives

Lisbon, Portugal
15-16 September 2023

CO-CHAIRS  
Nicoletta Colombo, Italy  
Philipp Harter, Germany

SPEAKERS  
Christina Fotopoulou, United Kingdom  
Antonio González Martín, Spain  
Charlie Gourley, United Kingdom  
Roberta Lazzari, Italy  
Xavier Matias-Guiu, Spain  
Xavier Paoletti, France  
Isabelle L. Ray-Coquard, France

LEARNING OBJECTIVES

• To learn about best clinical practice in the multidisciplinary management of early and late stage ovarian cancer
• To understand the importance of biology and pathology of common and rare ovarian tumours
• To understand the options for treatment of recurrent disease and how treatment decisions are made
• To understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
• To learn about the management of patients with symptoms of the disease and the side effects of treatment

ACCREDITATION

The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from GSK.

ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano  
Switzerland  
Email: courses@esmo.org  
www.esmo.org
## Friday, 15 September 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:10</td>
<td>Welcome and introduction</td>
<td>Nicoletta Colombo, IT Philipp Harter, DE</td>
</tr>
<tr>
<td>09:10-09:30</td>
<td>SESSION 1  Early stage – Part I</td>
<td>Nicoletta Colombo, IT Philipp Harter, DE</td>
</tr>
<tr>
<td>09:30-10:25</td>
<td>SESSION 2  Rare cancers – Part I</td>
<td>Nicoletta Colombo, IT Philipp Harter, DE</td>
</tr>
<tr>
<td>10:25-10:55</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>10:55-13:00</td>
<td>SESSION 3  Advanced disease at diagnosis</td>
<td>Nicoletta Colombo, IT Philipp Harter, DE</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>SESSION 4  Early stage – Part II</td>
<td>Nicoletta Colombo, IT Philipp Harter, DE</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>SESSION 5  Rare cancers – Part II</td>
<td>Nicoletta Colombo, IT Philipp Harter, DE</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 1: Early stage – Part I
- 20’ Clinical management of early ovarian cancer
  - Speaker: Isabelle L. Ray-Coquard, FR

### SESSION 2: Rare cancers – Part I
- 20’ Germ cells tumours
  - Speaker: Isabelle L. Ray-Coquard, FR
- 20’ Sex-cord stromal tumours
  - Speaker: Isabelle L. Ray-Coquard, FR
- 15’ Q&A
  - Audience: All

### SESSION 3: Advanced disease at diagnosis
- 20’ Biology of high-grade tubo-epithelial cancers, including biomarkers in practice
  - Speaker: Xavier Matias-Guiu, ES
- 20’ Surgery for newly diagnosed advanced ovarian cancer
  - Speaker: Christina Fotopoulou, UK
- 40’ First-line chemotherapy (including maintenance) treatment
  - Speaker: Nicoletta Colombo, IT
- 15’ Q&A
  - Audience: All
- 30’ Participants clinical case discussion (3x10’)
  - Speaker: Faculty

### SESSION 4: Early stage – Part II
- 20’ Overview on pathology, classification of early epithelial carcinoma
  - Speaker: Xavier Matias-Guiu, ES
- 10’ Q&A
  - Audience: All
- 20’ Surgery for early ovarian cancer: Staging
  - Speaker: Philipp Harter, DE
- 10’ Q&A
  - Audience: All

### SESSION 5: Rare cancers – Part II
- 20’ Rare epithelial tumours: Low-grade serous, clear cell and mucinous
  - Speaker: Charlie Gourley, UK
- 10’ Q&A
  - Audience: All
Saturday, 16 September 2023

<table>
<thead>
<tr>
<th>09:00-10:15</th>
<th>SESSION 7</th>
<th>Nicoletta Colombo, IT Charlie Gourley, UK</th>
</tr>
</thead>
<tbody>
<tr>
<td>90’</td>
<td>Recurrent disease and complex cases – Part II</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Management of ovarian cancer in older and frail patients</td>
<td>Antonio González Martín, ES</td>
</tr>
<tr>
<td>20’</td>
<td>Fertility-sparing surgery: A clinical case</td>
<td>Nicoletta Colombo, IT</td>
</tr>
<tr>
<td>20’</td>
<td>Role of HIPEC in ovarian cancer</td>
<td>Philipp Harter, DE</td>
</tr>
<tr>
<td>15’</td>
<td>Q&amp;A</td>
<td>All</td>
</tr>
</tbody>
</table>

10:15-10:45 Coffee break

<table>
<thead>
<tr>
<th>10:45-12:05</th>
<th>SESSION 8</th>
<th>Antonio González Martín, ES Charlie Gourley, UK</th>
</tr>
</thead>
<tbody>
<tr>
<td>80’</td>
<td>Biology and methodologies: All we need to develop future strategies</td>
<td></td>
</tr>
<tr>
<td>40’</td>
<td>Drug resistance and how to overcome PARP inhibitors resistance</td>
<td>Charlie Gourley, UK</td>
</tr>
<tr>
<td>25’</td>
<td>Clinical trial design, meta-analysis, PRO and QoL</td>
<td>Xavier Paoletti, FR</td>
</tr>
<tr>
<td>15’</td>
<td>Q&amp;A</td>
<td>All</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12:05-12:45</th>
<th>SESSION 9</th>
<th>Nicoletta Colombo, IT Philipp Harter, DE</th>
</tr>
</thead>
<tbody>
<tr>
<td>40’</td>
<td>Future treatments</td>
<td></td>
</tr>
<tr>
<td>25’</td>
<td>Novel treatment pathways and combinations: Horizon scanning</td>
<td>Antonio González Martín, ES</td>
</tr>
<tr>
<td>15’</td>
<td>Q&amp;A</td>
<td>All</td>
</tr>
</tbody>
</table>

12:45-13:00 Q&A All

13:00-14:00 Lunch

Note: Each 10-minute slot for clinical case discussion includes a 5’ case presentation and 5’ Q&A / panel discussion